#958
Retatrutide: Weight Loss #958
I’d trust Lilly’s trial data over the hype around microdosing retatrutide. The scientists who developed it know the molecule better than we do and the 1 mg dose studied in Phase 2 didn’t make it into Phase 3. “Triple agonist” doesn’t mean superior weight loss at every dose. And comparing results across separate trials doesn’t prove it beats or loses to semaglutide. The excitement around reta isn’t evidence that tiny doses work like magic.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Stay informed
New confessions and analysis, weekly.
Related confessions
Have your own story?
Anonymous. We publish roughly 1 in 10.